The outlay, plus up to $1.1 billion in milestones, has secured Takeda ex-China rights to a molecule that could compete with ...
Ipsen has gambled up to $610 million on a new class of bispecific T-cell engagers. The biobuck bet has landed the French ...
Physics, makers of diagnostic radiopharmaceuticals and molecular imaging agents. | GE HealthCare plans to take full control ...
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...
Novocure has cleared a phase 3 clinical study in pancreatic cancer, showing its tumor-treating electric fields could help ...
Cancer-focused Alligator Bioscience is clamping down on costs, laying off 70% of its team in efforts to save around $6 ...
Each year, we assemble our list of marquee names in the Fierce 15—featuring the most innovative private companies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback